Full-Time

Chapter Lead

Head of SBX Assays

Posted on 5/8/2026

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

Compensation Overview

$221.5k - $411.7k/yr

+ Bonus

Pleasanton, CA, USA + 1 more

More locations: Santa Clara, CA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • You have a PhD or MD/PhD in Molecular Biology, Oncology, Genetics (or related fields)
  • 12 or more years in molecular diagnostics
  • Proven track record of launching one or more NGS-based clinical assays (IVD or high-complexity laboratory-developed test)
  • Demonstrated experience managing large multidisciplinary scientific teams for 7+ years
  • NGS Mastery: Deep expertise in library preparation (e.g., Unique Molecular Identifier tagging, hybrid capture) and their direct impact on clinical sensitivity and limit of detection
  • Clinical Vision: Comprehensive understanding of the Cancer Continuum, including solid tumor profiling, hematological malignancies, and the nuances of liquid biopsy
  • Regulatory Experience: Proven track record of navigating the Design Control process (21 CFR 820) and launching at least one NGS-based clinical assay (IVD or high-complexity LDT)
  • Technical Diplomacy: Exceptional ability to navigate complex stakeholder environments; influence and guide senior functional experts who do not directly report to you
  • Scientific Presence: A sustained record of innovation, evidenced by high-impact peer-reviewed publications or patents in ctDNA, methylation, or early detection
  • Business acumen: Experience in portfolio prioritization and resource allocation within a matrixed R&D organization
  • Travel Requirements: ability to travel 15 - 20% of time to fulfill various business needs, including global oncology conferences and customer meetings
Responsibilities
  • Oncology Product Roadmap: Partner with Executive Leadership and Business teams to identify high-value clinical unmet needs and translate them into a multi-year technology roadmap
  • Strategic Execution: Drive end to end development of proprietary oncology assays, including defining performance requirements (LOD, sensitivity, specificity) that exceed current market standards
  • Product Realization & Scale: Oversee the critical transition of assays from R&D into a CLIA/CAP or IVD-regulated environment, ensuring manufacturability and operational scalability
  • Assay Innovation & De-risking: Implement and de-risk emerging technologies for use in clinical applications (e.g., epigenetics, fragmentomics, multi-omics)
  • Regulatory: Partner with Regulatory and Quality teams to design analytical validation studies (LoD, LoB, Precision) that meet FDA/PMA standards for Breakthrough Device designations
  • Evidence Generation & KOL Engagement: Help define the clinical evidence strategy required for medical utility based on high-level scientific exchange with top-tier academic centers and biopharma partners
  • Bioinformatics Integration: Architect the interface between wet-lab chemistry and Computational Biology to optimize the "sample-to-variant" pipelines, focusing on digital error suppression and signal-to-noise optimization
  • Operational Leadership: Drive 'Best-in-Class' technical standards across the organization, ensuring consistency in assay development methodologies and cross-functional alignment on technical KPIs
  • Value Communication: Present scientific and clinical value propositions at webinars, workshops, or customer meetings
  • People & Culture: Foster a "Culture of Rigor" that balances rapid prototyping with the disciplined documentation required for regulated medical products
Desired Qualifications
  • You have demonstrated strong interpersonal and communication skills with the ability to communicate complex technical knowledge in a clear and understandable manner to a multidisciplinary team.
  • You have demonstrated leadership experience
  • You have demonstrated experience in the AI/ML/Computational space
  • You have strong problem-solving skills with the ability to work independently
  • You have excellent written and verbal communication skills to effectively influence cross-functional stakeholders.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • CT-388 targets double-digit share in obesity market alongside Novo Nordisk and Lilly.
  • PathAI $750M acquisition scales AI digital pathology globally by late 2026.
  • Elecsys pTau217 Alzheimer's blood test launches in CE markets from July 2026.

What critics are saying

  • Rituxan patent expiry lets Sandoz biosimilars slash 40% lymphoma share in 6-12 months.
  • Swiss franc 12% rise compresses US 55% revenues as hedges expire in 6-18 months.
  • US IRA forces 60-80% discounts on Herceptin, Avastin from 2028, cutting $4B cashflow.

What makes Roche unique

  • Roche integrates pharmaceuticals and diagnostics via 1991 PCR acquisition from Cetus.
  • 1990 Genentech majority stake pioneered oncology antibodies like Herceptin and Rituxan.
  • Personalized healthcare strategy couples diagnostics to targeted therapies since 2009 full acquisition.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Roche who can refer or advise you

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.